Pneumococcal Vaccination and Pneumonia: Even a Low Level of Clinical Effectiveness Is Highly Cost?Effective
Open Access
- 15 December 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (12) , 2078-2079
- https://doi.org/10.1086/324356
Abstract
Most studies of the cost-effectiveness of pneumococcal vaccination show very favorable cost-effectiveness ratios for preventing pneumococcal pneumonia, but they make the controversial assumption that vaccination is equally effective in preventing bacteremic (BPP) and nonbacteremic (NBPP) pneumonia. However, the results of our study showed that, compared with preventing BPP alone, the cost-effectiveness of pneumococcal vaccination increased substantially even when only a small proportion of additional cases of NBPP were prevented.Keywords
This publication has 5 references indexed in Scilit:
- Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European CountriesClinical Infectious Diseases, 2000
- The Health and Economic Benefits Associated With Pneumococcal Vaccination of Elderly Persons With Chronic Lung DiseaseArchives of internal medicine (1960), 1999
- The clinical effectiveness of pneumococcal vaccination:Vaccine, 1999
- Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.Clinical Infectious Diseases, 1998
- Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly peoplePublished by American Medical Association (AMA) ,1997